Related Experiment Video
Updated: Jul 6, 2026
08:52
Isolation and Enrichment of Liver Progenitor Subsets Identified by a Novel Surface Marker Combination
Published on: February 18, 2017
Hepatic transit time in benign liver lesions
T Haendl1, D Strobel, N Steinebrunner
1Medicine 1, University of Erlangen Nuremberg. thomas.haendl@med1.imed.uni-erlangen.de
Ultraschall in Der Medizin (Stuttgart, Germany : 1980)
|April 3, 2008
Summary
Hepatic transit time (HTT) is shorter in patients with liver metastases than in those with benign liver lesions. An HTT over 10 seconds may rule out liver metastasis, indicating further liver evaluation is needed if HTT is less than 10 seconds.
Area of Science:
- Hepatology
- Medical Imaging
- Diagnostic Techniques
Background:
- Shortened hepatic transit time (HTT) of echo enhancers suggests liver metastasis.
- Previous studies indicate distinct HTT differences between metastatic and non-metastatic livers.
- The impact of benign liver lesions on HTT remains unclear.
Purpose of the Study:
- To compare the HTT in patients with benign liver lesions versus liver metastases.
- To clarify the influence of benign liver tumors on HTT.
- To differentiate between metastatic and benign liver lesions using HTT.
Main Methods:
- Patients with focal liver lesions were assessed.
- Echo enhancer (Sonovue) HTT was measured using time-intensity curves (TIC) in pulse inversion mode.
- HTT was calculated as the time difference between echo enhancer arrival in the hepatic artery and hepatic vein.
Main Results:
- 42 patients were studied: 19 with metastases, 23 with benign lesions.
- Mean HTT was significantly lower in liver metastasis patients (6.4 ± 1.6 sec) compared to benign lesions (10.4 ± 3.4 sec) (p < 0.001).
- No patients with liver metastasis exhibited an HTT exceeding 10 seconds.
Conclusions:
- An HTT exceeding 10 seconds appears to exclude liver metastasis.
- An HTT below 10 seconds warrants further liver evaluation.
- Benign liver lesions also shorten HTT, but to a lesser extent than metastases.
Related Concept Videos
01:02Noncompartmental Analysis: Mean Transit, Absorption and Dissolution Time
When drugs are administered extravascularly, a comprehensive evaluation through noncompartmental analysis becomes imperative. This analytical approach considers various parameters that play a crucial role in understanding the pharmacokinetics of these drugs.
One of the key parameters is the mean transit time (MTT), which refers to the total duration required for drug molecules to transit through the body. MTT is determined by calculating the ratio of the area under the moment curve to the area...
One of the key parameters is the mean transit time (MTT), which refers to the total duration required for drug molecules to transit through the body. MTT is determined by calculating the ratio of the area under the moment curve to the area...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:14Hepatic Drug Clearance: Role of Transporters
In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:07Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion, mediated...
A recent model describes pravastatin's hepatobiliary excretion, mediated...
01:17Hepatic Drug Excretion: Enterohepatic Cycling
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...